Cargando…

Hepatitis B Virus X Protein (HBx) Suppresses Transcription Factor EB (TFEB) Resulting in Stabilization of Integrin Beta 1 (ITGB1) in Hepatocellular Carcinoma Cells

SIMPLE SUMMARY: Worldwide, there are more than 800,000 liver cancer patients each year, with more than 700,000 annual deaths. Chronic infection of hepatitis B virus (HBV) contributes to about 70% of the liver cancers. HBV-encoded regulatory protein hepatitis B virus X protein (HBx) is well known for...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chunyan, Yang, Huan, Pan, Liwei, Zhao, Guangfu, Zhang, Ruofei, Zhang, Tianci, Xiao, Zhixiong, Tong, Ying, Zhang, Yi, Hu, Richard, Pandol, Stephen J., Han, Yuan-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967237/
https://www.ncbi.nlm.nih.gov/pubmed/33803301
http://dx.doi.org/10.3390/cancers13051181
Descripción
Sumario:SIMPLE SUMMARY: Worldwide, there are more than 800,000 liver cancer patients each year, with more than 700,000 annual deaths. Chronic infection of hepatitis B virus (HBV) contributes to about 70% of the liver cancers. HBV-encoded regulatory protein hepatitis B virus X protein (HBx) is well known for its pleiotropic roles in oncogenesis, in part through promoting viral replication, as well as hijacking host signal transduction pathways. In this study, we observed that lysosomal components and its transcription factor EB (TFEB) were downregulated in hepatocellular carcinoma (HCC) patients. Here, we uncovered a potential mechanism showing HBx-induced oncogenesis may be mediated by downregulation of TFEB, leading to malignant dissemination. ABSTRACT: Hepatitis B virus (HBV) infection is a major etiological risk for the incidence of hepatocellular carcinoma (HCC), and HBV X protein (HBx) is essential for oncogenic transformation. It is not known that if HBx can sabotage the lysosomal system for transformation and tumorigenesis, or its mechanism if it does have an effect. Examining clinical data, we observed that the downregulation of lysosomal components and transcription factor EB (TFEB) was associated with a poor prognosis of HCC patients. In HCC cells, we found that expression of HBx suppressed TFEB, impaired biogenesis of autophagic-lysosome, and promoted cellular dissemination. HBx mediated downregulation of TFEB led to impairment of autophagic/lysosomal biogenesis and flux, and consequently, accumulation of integrin beta 1 (ITGB1) for motility of HCC cells. Conversely, TFEB, in a steady-state condition, through induction of lysosomal biogenesis restrained ITGB1 levels and limited mobility of HCC cells. Specifically, overexpression of TFEB upregulated and activated the cysteine proteases including cathepsin L (CTSL) to degrade ITGB1. Conversely, expression of cystatin A (CSTA) or cystatin B (CSTB), the cellular inhibitors of lysosomal cysteine proteinases, spared ITGB1 from degradation and promoted dissemination of HCC cells. Taken together, this study suggests a potential mechanism for HBV-mediated malignancy, showing that HBx mediated downregulation of TFEB leads to accumulation of ITGB1 for HCC cell migration.